- SynonymCTLA4,CD152
- SourceHuman CTLA-4, His Tag (CT4-H5229) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Phe 162 (Accession # NP_005205.2).Predicted N-terminus: Ala 37Request for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 15.4 kDa. The protein migrates as 20-25 kDa under reducing (R) condition (SDS-PAGE) due to different extent glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 6 months under sterile conditions after reconstitution.
Human CTLA-4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human B7-1, Fc Tag (HPLC-verified) (Cat. No. B71-H5259) at 2 μg/mL (100 μL/well) can bind Human CTLA-4, His Tag (Cat. No. CT4-H5229) with a linear range of 0.2-4 ng/mL (QC tested).
Immobilized Human B7-2, Fc Tag (Cat. No. CD6-H5257) at 2 μg/mL (100 μL/well) can bind Human CTLA-4, His Tag (Cat. No. CT4-H5229) with a linear range of 1-6.4 ng/mL (Routinely tested).
Yervoy (Ipilimumab, Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CTLA-4, His Tag (Cat. No. CT4-H5229) with an affinity constant of 25.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
- Citations
PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS
Authors: C Beil, K Engel, G Hessler, et al.
Journal: US20200255540A1 2020
Application: SPR
Request for Full-text
Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR
Authors: Simons JF, Lim YW, Carter KP, et al
Journal: Mabs 2020
Application: Flow cytometry
Request for Full-text
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
Authors: Ganesan A, et al
Journal: Sci Rep 2019
Application: SPR
Request for Full-text
Therapeutic monoclonal antibodies in human breast milk: a case study
Authors: Ross E, et al.
Journal: Melanoma Res 2014
Application: ELISA
Request for Full-text
- BackgroundCTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.
- References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
